Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pharmacokinetics Study of CM310 Recombinant Humanized Monoclonal Antibody Injection in Healthy Subjects

NCT06171048 is registered in ClinicalTrials.gov with Keymed Biosciences Co.Ltd as lead sponsor.

NCT NCT06171048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06171048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pharmacokinetics Study of CM310 Recombinant Humanized Monoclonal Antibody Injection in Healthy Subjects
Lead sponsor
Keymed Biosciences Co.Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2024
Completion date
April 30, 2025
Enrollment
236 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy